GlassScriptPhysician profile
Ingrid Trenkle
NPI 1629161260
$29,400.47
in general payments reported to CMS, 2019-2025
45 companies · $2,756 in 2025
The $2,756 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,270 · 2020: $1,324 · 2021: $1,997 · 2022: $6,057 · 2023: $3,220 · 2024: $4,777 · 2025: $2,756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,561.86 |
| Education | $191.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $5,782.25 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Pfizer INC. | $4,308.73 | 2019-2025 | |
| Leo Pharma INC. | $2,469.40 | 2019-2025 | Adbry, Anzupgo |
| Abbvie INC. | $2,229.42 | 2019-2025 | Skyrizi, Rinvoq, Botox |
| Biofrontera INC. | $2,064.10 | 2019-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Genzyme Corporation | $1,039.09 | 2019-2025 | |
| Amgen INC. | $958.48 | 2019-2025 | Otezla, Otezla |
| Lilly USA, LLC | $895.96 | 2020-2025 | Olumiant, Taltz, Ebglyss |
| Novartis Pharmaceuticals Corporation | $831.06 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $771.84 | 2020-2025 | Dupixent, Libtayo |
| Revance Therapeutics, INC. | $708.88 | 2024-2025 | Daxxify |
| Arcutis Biotherapeutics, INC. | $668.16 | 2023-2025 | Zoryve |
| Almirall LLC | $665.57 | 2019-2025 | Klisyri |
| Dermavant Sciences, INC. | $587.30 | 2022-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $497.35 | 2019-2025 | Winlevi |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ingrid Trenkle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.